Operator of a pharmaceutical company intended to develop fluorine-based novel, safer and more effective medicine. The company's services include developing small molecule product portfolio for Multiple Myeloma, Waldenström's Macroglobulinemia, Leukemia, Glioblastoma, Lung and Pancreatic Cancers and Central Nervous System disorders, enabling patients to avail therapeutics to treat and avoid cancer diseases.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Merger/Acquisition | 27-Jan-2016 | $31.7M | 00.000 | 000.00 | Completed | Generating Revenue |
3. Early Stage VC | 07-Jan-2015 | 00.000 | Completed | Generating Revenue | ||
2. Early Stage VC | 07-Jun-2012 | $1.47M | $1.47M | Completed | Generating Revenue | |
1. Accelerator/Incubator | 01-Jan-2010 | Completed | Generating Revenue |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
FACIT | Venture Capital | Minority | 000 0000 | 000000 0 | |
Ontario Institute for Cancer Research | Not-For-Profit Venture Capital | Minority | 000 0000 | 000000 0 | |
StandUp Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |